Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE.
Kileel EM, Malvestutto CD, Zanni MV, Davies-Smith E, Fichtenbaum CJ, Lake JE, Lo J, Aberg JA, Martinez E, Patel K, Bloomfield GS, Chu SM, Awwad A, Diggs MR, Lu AB, Bares SH, Berrner D, Smieja M, Okeke NL, Kumar P, João E, Currier JS, Lu MT, Fox MP, Brennan AT, Douglas PS, Grinspoon SK, Ribaudo HJ.
Kileel EM, et al. Among authors: douglas ps.
Lancet HIV. 2026 Mar 27:S2352-3018(25)00354-6. doi: 10.1016/S2352-3018(25)00354-6. Online ahead of print.
Lancet HIV. 2026.
PMID: 41911941
Free article.